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Abstract
Background: Mass drug administration (MDA) is a suggested mean to accelerate efforts towards elimination and
attainment of malaria-free status. There is limited evidence of suitable methods of implementing MDA programme to
achieve a high coverage and compliance in low-income countries. The objective of this paper is to assess the impact
of this MDA delivery strategy while using coverage measured as effective population in the community and popula‑
tion available.
Methods: Population-based MDA was implemented as a part of a larger program in a high transmission setting in
Uganda. Four rounds of interventions were implemented over a period of 2 years at an interval of 6 to 8 months. A
housing and population census was conducted to establish the eligible population. A team of 19 personnel con‑
ducted MDA at established village meeting points as distribution sites at every village. The first dose of dihydroarte‑
misinin–piperaquine (DHA-PQ) was administered via a fixed site distribution strategy by directly observed treatment
on site, the remaining doses were taken at home and a door-to-door follow up strategy was implemented by com‑
munity health workers to monitor adherence to the second and third doses.
Results: Based on number of individuals who turned up at the distribution site, for each round of MDA, effective cov‑
erage was 80.1%, 81.2%, 80.0% and 80% for the 1st, 2nd, 3rd and 4th rounds respectively. However, coverage based
on available population at the time of implementing MDA was 80.1%, 83.2%, 82.4% and 82.9% for rounds 1, 2, 3 and
4, respectively. Intense community mobilization using community structures and mass media facilitated community
participation and adherence to MDA.
Conclusion: A hybrid of fixed site distribution and door-to-door follow up strategy of MDA delivery achieved a high
coverage and compliance and seemed feasible. This model can be considered in resource-limited settings.
Keywords: Malaria, Mass drug administration, High transmission setting, Uganda
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Background
Although the malaria burden is declining in several
countries [1, 2], malaria-related morbidity and mortality remains high in sub-Saharan African countries, such
as Uganda [1–6]. In the 2018 World Malaria Report,
the sub-Saharan region contributed 92% of the global
219 million cases, with Uganda accounting for 4% of
these cases. There are numerous efforts by the Uganda
National Malaria Control Programme (UNMCP) to scale
up recommended malaria control interventions including long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS), intermittent preventive treatment
in pregnancy (IPTp) and case management using artemisinin-based combination therapy (ACT). In spite of all
the effort, malaria reports indicate a raising incidence in
Uganda [7, 8].
Uganda, as a stably endemic, high burden country with
pockets of extremely high malaria transmission faces
the challenge of charting a rapid and safe route from a
high malaria transmission zone towards pre-elimination
phase via an intermediate low transmission state. In
this regard there is a renewed interest in using malaria
mass drug administration (MDA) to rapidly reduce the
malaria burden and hasten the path to pre-elimination
[9–11]. Whereas the WHO recommends use of MDA
in low transmission settings [12], in the context of this
study, MDA was used in combination with indoor residual spraying (IRS) to test how to accelerate reduction of
malaria transmission. The impact of MDA on malaria
burden will be reported elsewhere.
To impact on transmission, MDA requires high coverage of the target population which, in turn, demands a
high level of community participation and engagement.
MDA aims to provide therapeutic concentrations of antimalarial drugs to a proportion of the population as large
as possible in order to cure asymptomatic infections and
to prevent re-infection during the period of post-treatment prophylaxis. MDA should be conducted in a coordinated manner, so that the drug is taken at approximately
the same time by the whole population at risk, often at
repeated intervals [13]. The current recommended MDA
delivery strategies are door-to-door strategy and centralized, fixed site strategy [13]. Uganda has implemented
MDA for river blindness, intestinal worms and onchocerciasis in communities and schools employing door-todoor strategy for the past 8 years [14]. In all these, MDA
is delivered by village health team (VHT) and the drugs
distributed are single doses not based on weight. MDA
for malaria with a three-day weight-based regimen poses
logistical challenges of ensuring appropriate dosing and
completion. The choice of strategy may majorly depend
on the local circumstances and should be defined bearing in mind the context for each area in country. The
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objective of this paper is to assess the impact of the MDA
delivery strategy while using coverage measured as a proportion of the effective population and population available at the time of implementing MDA.

Methods
MDA for malaria was administered in the framework of a clinical trial assessing the additional population impact of adding MDA to an IRS intervention in a
high malaria transmission setting in Uganda (PACTR
201807166695568). Consent to participate was obtained
from all participants prior to taking MDA. The study
was approved by the Makerere University School of Public Health Higher Degrees Research Ethics Committee
(MUSPH-HDREC) protocol reference number 327 and
the Uganda National Council for Science and Technology
(UNCST).
Study setting

The study was conducted in Kapujan sub-county, Katakwi
district, in North-Eastern Uganda. Kapujan sub-county
lies along the shores of Lake Bisina, a fingerling of Lake
Kyoga. The malaria prevalence in the area occurs all the
year round. MDA was implemented in a study assessing
the impact of population-based MDA given in combination with IRS or IRS alone. Four rounds of interventions
were implemented over a period of 2 years. The first
round was implemented in November–December 2016,
the second in August 2017 the third from April–May
2018 and the fourth from November–December 2018.
Study area and population

Farming is the main economic activity with occasional
fishing. The area has 18 villages and each village has on
average 5 to 6 village health team members (VHT). The
VHTs serve to improve timely access to health care particularly for children under 5 years and pregnant mothers. The area has one health centre-III, and 2 heath
centres IIs which are second and first line health units
in the health care service delivery structure, respectively.
The sub-county had universal mass distribution of LLINs
in 2017 in addition to the study interventions.
MDA implementation
Community engagement

Community awareness was created about MDA aimed at
securing commitment and participation of all stakeholders. Community engagement commenced by meeting
and sensitizing the district leadership including the District Health Officer, District Education Officer, the Chief
Administrative Officer, the Resident District Commissioner, the District Malaria Focal Person and the District
Health Management Team members. Community leaders
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were sensitized on the study objectives, interventions
and the expected role of the community. Sensitization
meetings were further held with sub county and village
leaders. Community members were sensitized in village
meetings. Information was provided about malaria prevention methods with a focus on MDA and its implementation. The rational of giving drugs to healthy people
during MDA for prevention of malaria was emphasized.
Community members were further informed on how
to take the medicine, importance of completing the full
dose, the expected drug reactions and the need to report
these to the study team. During these meetings, study
objectives, procedures, benefits and risks were comprehensively discussed and community members were given
a chance to ask questions to which responses were made
by the study team. Other mobilization strategies included
radio announcements, radio spots, and use of mobile
mega microphones. Interpersonal communication by
the Local Council leaders (LCs) and VHTs continued
throughout the implementation period.

implementation of MDA. Assent was obtained from children aged 8 to 17 years. Due to the dynamic nature of the
study population, the enumeration database was updated
before each round of the exercise. New households
were mapped and members enumerated and screened.
Old households were checked to update information in
case some individuals left, died or new ones came in the
study area and to update the eligibility of all household
members.

Hiring and training study staff

MDA coordination

A total of 108 VHTs, who are part of the existing health
system structure, were recruited to help with community mobilization effort. In addition, 60 study staff were
hired to work at distribution sites during implementation of MDA. Of these, 30 were data officers and 30 were
health workers with variable training (nursing assistants,
registered nurses, midwives, laboratory technicians and
clinical officers). All were trained on performance of their
roles at the distribution sites, conduct of the door-todoor follow up, and the study standard operating procedures (SOPs). All staff had a 4 days certified good clinical
practice (GCP) training. The training included a pilot
dry run. A team of 19 people conducted the exercise per
village.

The team comprised of an overall coordinator, sector
supervisors, team leaders, health workers, data officers
and VHTs (Fig. 1). A total of six teams were deployed to
cover 18 villages over a period of 15 days. Each team had
19 personnel comprising a team leader, 5 health workers,
4 data officers and 9 VHTs. MDA was conducted by one
team in each village over a period of 5 days. One sector
supervisor was assigned to oversee 2 teams and ensured
adequate supply of logistics and adherence to standard
operating procedures (SOPs). Teams were systematically
deployed in sequence. Each sector supervisor initiates
one team at a time, after the second day of distribution,
the second team would commence work in the next village. Once a team completes work over the 5 days, they
would move to another village.

Enumeration of households

All households in the study area were mapped using hand
held global positioning system (GPS) devices. Household members enumerated using hand held computers
uploaded with Survey be software version (EDI-group,
version 8, UK). Data was retrieved each day and stored
on a central computer at the study office. Households and
household members were assigned a unique identifier
using a barcode system. Each individual’s barcode was
attached to an individual card that is presented at the distribution site for individual verification. Individuals were
screened to ascertain study eligibility. Children below
6 months and pregnant women were excluded as well as
adults with history of chronic conditions like kidney and
livers diseases. Consent to participate in the study was
obtained from all potential study participants prior to

Logistics and supplies

Team leaders ensured that all logistical supplies were
available. A checklist was used to organize, issue and
account for equipment and supplies designated for each
fixed point. Each team was assigned a vehicle, 3 computers, 2 barcode scanners, 12 chairs and 6 tables, 3 Jerrycans, disposable cups and spoons, study drugs, stationery
and laboratory supplies. The study drug was pre-packed
according to weight-based doses and stored in a secure
temperature controlled place.

Fixed site distribution

Fixed site delivery was implemented at established village
meeting points in the study area for directly observed
therapy (DOT) of the first dose. Village meeting points
were known places for routine meetings in a village. At
these meeting points, all eligible household members
were mobilized to go for 1st DOT dose and to receive the
2nd and 3rd doses. Each static point had 6 stations numbered 1 to 6 and each had specific tasks (Figs. 2, 3).
Station one was the registration point where participants were registered. Following registration, MDA treatment tracking forms were issued to each participant and
the participant’s particulars were written on the form.
Station two was participant’s identity verification
point. Each participant presented their individual study
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Fig. 1 MDA implementation structure

identification card holding a unique barcode for verification. Two data officers, using barcode scanners and
a computer verify each participant in the database, and
confirm whether they were screened for eligibility criteria and had provided consent to participate in the study.
On completion of the validating process, a mark was put
on each participant’s card to indicate, the individual had
reported to the distribution site. Those who had not consented during the enumeration exercise, were directed to
station three to obtain informed consent, all information
is recorded in the tracking form.
Station three was the point for seeking informed consent to participate in the study. Two study staff screened
participants and sought for informed consent, for those
who missed it during enumeration. The MDA treatment
tracking form was updated accordingly.
At station four; two study nurses screened for pregnancy in every female participant of reproductive age
(14–49 years). Urine samples were collected in urine
containers and tested using HCG kits. Any participant
who had a reactive pregnancy test was advised not to
take the study drug and referred to attend antenatal care.
The result was recorded on the MDA treatment tracking

form. Participants whose HCG test was not reactive continued to station five to receive the study drug. Participants who had symptoms of malaria, were tested with a
malaria RDT. The results (positive and negative) were
recorded on the MDA treatment tracking form and all
continued to station five.
At station five, three study nurses checked the eligibility of participants to take the study drug before dispensing the drugs. The study nurses checked for consent or
assent to participate in MDA and results for urine HCG
and malaria RDT tests where applicable. Those having a
positive malaria RDT test received artemether–lumefantrine, the first-line treatment for uncomplicated malaria
in Uganda, the rest received the study drug. Participant’s
weight was taken and the study drug dispensed according
to weight-based dosing. The first dose of treatment was
given as DOT for each participant. The second and third
doses were given to the participants with instructions to
take the drugs at home.
At station six, data officers collected MDA treatment
tracking forms from each participant. The barcode is
scanned to update records of administration of the 1st
DOT dose at site. This process updated the database
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Fig. 2 MDA distribution site map

instantly and provided information on real time coverage
for 1st dose DOT. At the end of each day, a list of those
who needed follow up to monitor adherence for the 2nd
and 3rd doses was generated as well as those who still
needed to be mobilized to come for the 1st dose.
MDA was conducted between 8th and 22rd December
2016 for round one, between 14th and 29th August 2017
for round two and 27th April to 10th May 2018 for round
three and 27th November to 12th December for round 4.
Door‑to‑door follow up

On the second day of distribution in a village, about 4
VHTs started door-to-door monitoring for treatment
adherence for the 2nd and 3rd dose and inquiring about
any adverse events in each village. VHTs also mobilized
individuals who did not turn up at the treatment points
and encouraged them to report for treatment within the
4 days of distribution. They provided household members with telephone numbers to call without paying
(hot lines), for communicating to the study team doctors in case of any symptoms after taking the study drug.

Adherence was monitored by checking for empty drug
blister packs. Tracking logs indicating participant’s completion of 2nd and 3rd doses were filled for each participant in a village. Participants were followed up in each
village for extra 2 days to record the taking the 2nd and
3rd doses.
Management of adverse events

Expected drug reactions and side effects were explained
to the community members at village meetings and by
use of radio talk shows. This communication was continuously provided during and after MDA implementation.
Two hotlines for calling study doctors were circulated
to community members during the meetings. When
a community member felt unwell, they contacted the
medical team through the hot lines, the team assessed
whether the participant experienced an adverse event or
a drug reaction. The medical team moves to the households to assess such study participants. Depending on
the assessment of the doctors, a vehicle was availed to
transport patients who needed to be managed in a health
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Fig. 3 Malaria treatment tracking form

facility. Both health facility staff and the study team doctors worked together to manage adverse events All complaints were documented using a standard adverse event
reporting form from the study drug manufacturer (Sigma
Tau) and the institutional review board (IRB). All adverse
events were managed following the standard of care and
were followed until they resolved. Prior to implementing
interventions, health facility staffs were trained in management of possible adverse events and complications of
the study drugs that were likely to be reported. Drugs and

other supplies were fully stocked to ensure appropriate
case management according to the country’s treatment
guidelines.

Results
Enumeration of study participants

The area has a population of 14,468 people based on
study enumeration data. About 52.0% of the population
is females and 57.0% are children under 15 years. The
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area has 2490 households with average house occupancy
of 5.5 persons per household.
MDA coverage

MDA coverage was estimated based on enumeration
updates, which were conducted before commencement
of interventions. Success of this delivery strategy was
measured by using effective coverage (coverage based on
all individuals who lived in the in past 6 months and plan
to live in the same community in the next 6 months.) and
coverage based on population available during the implementation of MDA. For effective coverage, MDA coverage was 80.1%, 81.2%, 80.0% and 80% for first, second,
third and fourth rounds of MDA respectively (Table 1).
Whereas coverage based on population available was
80.1%, 83.2%, 82.4% and 82.9% % for first, second, third
and fourth rounds, respectively. Coverage for each round
was based on number of individuals who turned up at the
distribution sites against number of individuals enumerated in the study area. Coverage at village level and factors affecting uptake of MDA in this setting is described
elsewhere. Adherence for round one was not monitored
as the implementation had an adaptive approach to try
and find a strategy that would adequately yield satisfactory results. For instance, the process was improved by
introducing monitoring of uptake of 2nd and 3rd doses
using tracking logs. Consequently, adherence to subsequent rounds was over 80% for second and third doses.
Lessons learn from round one were used to improve subsequent rounds.
Lessons learnt

Engaging the leadership at all levels provided community acceptance and improved willingness to participate
in MDA. Using VHTs, and local council leaders, in community mobilization, built confidence in the community
about MDA. Interpersonal communication by door-todoor mobilization conducted by local council leaders and

VHTs was very effective in mobilizing the community to
participate in the exercise.
Hiring local staff who knew the local language, facilitated effective communication between study staff and
study participants. Training study staff equipped them
with the necessary knowledge and acceptable practices
for handling study participants. Working with the community promoted ownership as everyone desired to
achieve a high coverage in their area.
Preparing logistics in time before commencement of
field activities was very important. Teams assigned to villages ensured high turn up at distribution sites and satisfactory follow up of 2nd and 3rd doses. This approach
did not only improve monitoring MDA activities but provided an opportunity for team work within each team.
Team work resulted in commitment by the study team,
local leadership and VHTs to ensure coverage is high in
villages which were assigned to them. It provided for adequate accountability for study drugs as well as logistical
supplies.
Fixed site distribution and door-to-door follow up was
effective in achieving a high MDA population coverage. It
facilitated close supervision to ensure adherence to SOPs
and participant safety. The delivery of drugs, test kits,
weighing scales, computers, scanners, treatment forms
and other supplies to the distribution sites was logistically feasible compared to when study staff would move
door-to-door with all these items. It is a logistically feasible approach for delivering MDA because of employing fewer personnel and minimal transport needs. This
approach both accommodated our resource constraints
and served as a knowledge sharing and capacity building
process within the research team.
Challenges

Additionally, implementing MDA during the rainy season is challenging because most community members were busy in their gardens. Inadequate duration

Table 1 Mass drug administration coverage in Kapujan sub-county, Katakwi district
Round 1 2016

Round 2 2017

Round 3 2018

Round 4 2018

N = 15,639a

N = 15,543a

N = 15,450a

N = 15,559a

Fixed distribution (DOT): number treated and percentage, 95% CI
Dose 1, DOT

12,523b

80.1 (0.794–0.807)

12,620b

81.2 (0.806–0.818)

12,366b

80.0 (0.794–0.807)

12,4449b

80.0 (0.794–0.806)

Door-to-door monitoring: number treated and percentage
Dose 2

–

–

12,488

80.1 (0.795–0.807)

12,344

79.9 (0.793–0.805)

12,399

79.7 (0.791–0.803)

Dose 3

–

–

12,444

80.1 (0.794–0.807)

12,343

79.9 (0.793–0.805)

12,399

79.7 (0.791–0.803)

Overall

80.1 (0.794–0.807)

81.2 (0.806–0.818)

a

Number of individuals living in the study area at the time of interventions

b

Number of individuals eligible to receive the study drug

80.0 (0.794–0.807)

80.0 (0.794–0.806)
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of engagement with the community before and during
implementation of MDA. This approach needed a large
amount of investment put in mobilizing the community.

Discussion
Population-based MDA was implemented using dihydroartemisinin-piperaquine (DHA-PQ) delivered by
fixed point distribution for the first dose and door-todoor follow up for the second and third doses in Kapujan
sub-county, an area of high malaria transmission in North
Eastern Uganda. Of the eligible persons at each round of
intervention, MDA coverage was 80.1%, 81.2%, 80.0%
and 80% for the 1st, 2nd 3rd and 4th rounds, respectively.
Treatment adherence to all three doses in round one, was
not captured but for subsequent rounds was over 80% for
second and third doses. Intense community mobilization
using community structures and mass media facilitated
community participation and adherence to MDA.
Community engagement was very critical during the
implementation process of MDA. Engaging the community about the importance of the project prior to
implementation of MDA increased participation among
the local leadership and the community members. Findings are similar to that in the Gambia, where sensitizing
the community increased participation in MDA project
[15]. Use of a collaborative approach to mobilize the
community by the study team in partnership with the
local leadership ensured community participation and
commitment to MDA implementation. This similarly
reported in Cambodia, [16] where community health
workers, community leaders and political leaders took a
central role in community mobilization for a successful
MDA implementation. Active community engagement,
as recommended by the WHO, is essential for any MDA
implementation plan.
Updating the household and population database
before each round of MDA provided an accurate population size to target for each round of MDA and enabled a more accurate estimate of MDA coverage in the
community. A literature review of other studies reports
unclear and inconsistent methods for estimating coverage [17]. Furthermore, screening for MDA eligibility and
getting participant consent during the enumeration process improved efficiency of the exercise. This exercise was
closely monitored by the study internal systems to ensure
that the information obtained about participants was
accurate and that there was no coercion to participate.
To carry out an organized MDA across all distribution
sites, a structure was developed to facilitate quick access
to logistics, close supervision and accountability of study
supplies. With little documentation of similar structures in other MDA settings, this structure may provide
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a working framework for organizing MDA distribution
sites in comparable settings in low-income countries.
A framework was created to allow consistent MDA
implementation at the distribution sites from station
1 to 6. This allowed MDA implementation in a consistent manner across all distribution sites. In the literature
reviewed, it was not possible to find any study with such
a flow plan, but the algorithm created was significant in
ensuring consistency in methodology and standardization of activities at distribution sites. Door-to-door follow up by VHTs was key in ensuring adherence to the
2nd and 3rd doses. The door-to-door follow up process
provided continuous contact between the individual participants and study team post 1st dose DOT. The collection of blister packs after each individual has taken their
2nd and 3rd doses was in some way to validate the number of doses given out and those taken.
Fixed site distribution for 1st dose and door-todoor monitoring of 2nd and 3rd doses was successful
in achieving a simultaneous high population coverage
within a period of 15 days. The proportion of the effective population that took the weight-specific dose at distribution sites under direct observation therapy (DOT)
was 80.1%, 81.2%, 80% and 80% for rounds 1, 2, 3 and 4
respectively. About 80.1%, 79.9% and 79.7% % reported
taking 2nd and 3rd doses during the door-to-door follow
up for MDA rounds 2, 3 and 4, respectively. The strategy
of door-to-door follow up could be among other factors contributing to ensuring participants complete the
3-day’s regimen compared to a fixed point distribution
alone. MDA implemented in two zones in Liberia during the Ebola outbreak documented much lower coverage of 52% and 22% for round 1 and 2, respectively [18].
In a study in Eastern Myanmar, fixed site distribution
using malaria posts, MDA participation achieved was
slightly over 60% in smaller villages and registered below
30% in larger villages [19]. In comparing to door-to-door
delivery with age-specific doses conducted in a study in
Sierra Leone [20], coverage of DOTs was 71% and 97.1%
coverage in a Zanzibar [21], while in the hybrid model
in this study DOTs was 81% and 76% and 80% in rounds
1, 2, and 3, respectively. Outwardly, a combination of
fixed site distribution with door-to-door follow up when
administering weight-specific doses, promotes compliance and is logistically feasible for reaching a large population at the same time. The WHO puts more emphasis
on the door-to-door MDA delivery strategy [13], which
may work well with age-specific doses although the logistics for its roll out are not well documented. It is likely
that in population-based MDA, logistics of carrying
computers, weighing scales, testing kits for pregnancy
and drugs may be an issue if door-to-door MDA delivery
is to be implemented. A combination of fixed distribution
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and door-to-door follow up strategy is recommended for
population-based MDA especially in countries with a
similar setting.
As much as guidelines or recommendations mention about pharmacovigilance in MDA, how to practically implement it is not well documented. In this study,
a field medical team in collaboration with health workers from health centres in the study area managed the
adverse events (AE). A study by Landier et al. reported
use of a medical team with a mobile clinic for monitoring and management of adverse events [22] during MDA.
In this study, hot lines for reporting adverse events to the
medical team were used. Management of adverse events
was carried out at the health facilities where drugs were
stocked, health workers were trained on management
of adverse events and proper documentation of adverse
events was done. This provided a logistically feasible and
an efficient surveillance system for monitoring adverse
events as existing structures in the health system were
used.
Timing for MDA implementation should target school
holidays and before the rainy season starts when the
community is less mobile [23]. Round one and round
four of MDA implementation was during the December
dry season and when school children were back home
for holidays, a high coverage was attained during these
rounds. A similar observation was made in The Gambia
[15] and they recommend that MDA activities be undertaken just before the rainy season.
The logistical complexities for implementing MDA
may need to change from place to place and from time to
time. The tools for MDA implementation need to allow
for sufficient flexibility to be adapted by all users in varying settings. With the dynamics of the population, there
will always be new challenges and new ways of coping.

Limitations
Although, MDA implementation was a success, several
limitations exist. In 2 out of the 3 rounds of implementation, MDA activities were conducted during the school
term, making it difficult to reach school children. At the
same time, the community was mobile due to activities
associated with the rainy season. LLIN and IRS campaign
conducted in the area could have influenced compliance
to MDA as the community could feel protected. This
could have also introduced intervention fatigue in the
community. Lack of capacity to closely monitor migration
of the population in and out of the study area may have
resulted into underestimation or overestimation of MDA
coverage. Managing perceptions of drug side effects was
complex as it was difficult to get everyone understand the
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difference between side effects and adverse events. It was
difficult to explain malaria transmission in relation to the
need to take drugs for a person who is not sick.

Conclusion
Using community structures for community sensitization and mobilization facilitates high participation in
MDA. Updates of mapping and enumeration database
before each round of interventions is essential for accurate estimate of coverage. Screening and consenting
during each round is key for identification of eligible
participants. Organizing teams based on number of villages and available resources helps to manage logistical
issues and supervision of processes. Fixed site distribution design, built on existing resources allows MDA site
distribution to be implemented in a consistent and standard manner across all distribution sites for 1st dose under
DOT. Door-to-door follow up by VHTs is key in ensuring
adherence to 2nd and 3rd doses and timely identification
and management of adverse events. A hybrid (Box 1) of
fixed site distribution for 1st dose under DOT and doorto-door monitoring promotes and simultaneously allows
assessment of adherence to and safety of the 3 days ACT
regimen.
Box 1: Summary of MDA distribution activities
Fixed site distribution
Door-to-door distribution
Organizing the site prior to
Verification of household
distribution
members
Verifying eligibility to take MDA
Explaining of objectives for the
Screening of women of reproduc‑
campaign
tive age for pregnancy
Obtained consent/assent
Registration of individuals receiv‑ Checking for eligibility
ing the study drug
Screening for pregnancy
Distribution of blisters with 1st
among women of reproduc‑
dose under DOT
tive age
Tally sheet completed after medi‑ Distribution of blisters appropri‑
cine has been dispensed
ate for the age category
Monitoring for serious adverse
Give instruction for taking the
events or Adverse events for at
remaining Doses on days two
least 30 min and
and three
Referral of all ill people to the
Mark the tally sheet
nearest health facility
Mark the completed house hold
Mix of two approaches
Organizing the sites to have facilities like, pit latrines, tables, chairs,
drinking water, shelter or waiting shades
Identification and verification of village members
Consenting and/or assenting
Screening for eligibility
Testing for pregnancy
Dispensing of drugs
All ill people referred to health facilities
Door-to-door follow up using tracking logs to identify people who
should be mobilized To go to the site for day 1 dose under DOT
Monitored the taking of 2nd or 3rd doses
Inquired about adverse events
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